A special study confirmed that this cell construct exhibits CAR-mediated, CD19-dependent activity against autologous B-cells and comparably low inflammatory cytokine production when derived from cells from SLE, SSc, and idiopathic inflammatory myositis (IIM) patients [98]. Here, CD19 is linked to systemic sclerosis.